Houdayer arrives as General Director beginning January 1, 2025, following a distinguished career at two of the world's leading consumer goods groups: Procter & Gamble and Henkel. His appointment signals a clear strategic intent — to reverse the revenue declines that have plagued Boiron since the cessation of homeopathic treatment reimbursements in France, and to reposition the company for long-term sustainable growth. Thierry Boiron will remain as Chairman of Boiron Développement, providing continuity within the founding family's involvement.
A Career Built on Consumer Brands
Pascal Houdayer's professional trajectory is a masterclass in building and scaling consumer brands across highly competitive international markets. His career began at Procter & Gamble in 1992, where he spent nearly two decades rising through marketing and general management roles. As marketing director for the laundry division across Europe and the United States, he oversaw some of the world's most recognizable household brands, developing a sharp understanding of consumer behaviour, retail dynamics, and mass-market positioning.
After leaving P&G in 2011, Houdayer brought his expertise to Henkel, where he served as General Manager of Henkel Beauty Care. His tenure there further honed his ability to manage a diversified portfolio of consumer brands in fast-moving categories — a skill set directly applicable to Boiron's ambitions to broaden beyond homeopathy.
Beyond these two major groups, Houdayer went on to lead the operations of Naos — the parent company of dermatological brands Bioderma and Institut Esthederm — and later founded Orveon Global in the United States, a beauty group born from the acquisition of brands spun off from Shiseido. Each step in his career reflects an ability to navigate complexity, whether turning around legacy brands or building new ventures from the ground up.
The Challenge Awaiting at Boiron
Laboratoires Boiron is a company defined by its heritage. Founded in Lyon in 1932 by twin brothers Jean and Henri Boiron, the company grew into the world's leading manufacturer of homeopathic medicines, distributing products in over 50 countries. For decades, it operated in a stable, predictable market, buoyed by reimbursements within the French healthcare system.
That stability came to an abrupt end when France's High Authority of Health (HAS) concluded that homeopathic treatments lacked sufficient clinical evidence to justify reimbursement. The government duly withdrew coverage, triggering a significant drop in domestic demand. Boiron responded with painful restructuring: workforce reductions, plant closures, and a sharp focus on cost management. Revenue declined, and the company found itself in need of a new strategic direction — and a new kind of leader.
Houdayer enters this environment not as a homeopathy specialist, but as a brand builder and market navigator. His mandate is less about defending what Boiron was, and more about defining what it can become.
Strategic Direction: Diversification and Repositioning
Boiron's stated strategy under its new leadership is to pursue diversification through adjacent health categories — most notably phytotherapeutic products (plant-based medicine) and nutritional supplements. These markets are growing rapidly as consumers across Europe and beyond seek natural alternatives to conventional pharmaceuticals, and they sit comfortably within the natural health positioning that Boiron has long cultivated.
Houdayer's background makes him well-suited to this pivot. Managing a brand transition — from a single-category specialist to a broader natural health platform — requires exactly the kind of portfolio thinking, retail relationships, and consumer insight he developed across three decades at P&G, Henkel, and Naos. He understands how to build trust with large retail partners, how to position products in a crowded marketplace, and how to communicate brand values to a sceptical but receptive audience.
The challenge will be to execute this diversification without diluting the credibility and recognition that Boiron's name still commands, particularly among loyal customers and healthcare professionals who remain advocates for integrative medicine approaches.
A Profile Shaped for Transition
What makes Houdayer's appointment particularly notable is the deliberate choice to look outside the pharmaceutical and homeopathy worlds for leadership. Boiron's board has opted for a profile defined by commercial agility and brand expertise rather than scientific specialisation — a sign that the company's priorities have shifted decisively toward market recovery and growth.
His experience founding Orveon Global is perhaps the most instructive. Building a new company from acquired assets requires vision, speed, and the ability to create coherence across a diverse portfolio — all qualities that Boiron will need as it assembles its new product strategy. Meanwhile, his years at Naos demonstrate familiarity with the health-adjacent consumer space, where scientific credibility and consumer trust must coexist with commercial ambition.
As Pascal Houdayer steps into one of France's most storied healthcare companies, the question is not whether he has the tools for the job — his career makes clear that he does — but whether Boiron's culture, history, and market positioning can be successfully reframed around a broader vision of natural health. The first chapters of his tenure will be defining.